15% OFF CJC-1295 (No DAC) + Ipamorelin – 20mg/vial (10mg + 10mg) (Research Use Only)
A fixed two-compound preparation of CJC-1295 without DAC (a GHRH analogue) and ipamorelin (a selective GHSR-1a agonist), 10mg of each per vial. Supplied for laboratory research and identification purposes only.
Availability: In stock
3–4 vials — 5% off · 5–9 vials — 10% off · 10+ vials — 15% off
Applied automatically in the cart. Combines with a discount code up to 20% off in total, and stacks on top of the subscription discount.
Research Disclaimer: All products currently listed on this site are for research purposes only.
Overview
This vial is a fixed two-compound preparation containing 10mg of CJC-1295 without DAC (Modified GRF 1-29, a GHRH analogue) and 10mg of ipamorelin (a selective GHSR-1a agonist), for 20mg of total peptide per vial. The two compounds act at separate receptors — the GHRH receptor and the ghrelin receptor respectively — and the pairing appears in the published endocrine pharmacology literature as a model for studying concurrent stimulation of both pathways.
What It Is
CJC-1295 (No DAC) is a 29-amino acid synthetic analogue of GHRH(1-29) with substitutions at positions 2, 8, 15 and 27 that confer resistance to dipeptidyl peptidase IV. It carries no Drug Affinity Complex, so it does not bind albumin and has a short half-life profile. Molecular weight approximately 3,368 Da.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH₂), molecular weight approximately 711 Da, characterised in published pharmacology as a selective agonist at the growth hormone secretagogue receptor type 1a without meaningful ACTH, cortisol or prolactin co-stimulation in pituitary cell systems.
Research Spotlight
Published research has used GHRH-receptor agonists and ghrelin-receptor agonists together to examine how the two receptor pathways interact at the pituitary somatotroph. Study designs in the literature include receptor binding and cAMP assays, pituitary cell culture, and GH pulse-kinetics work in rodent and porcine models. Each compound is also available individually in the Portal to Wellness catalogue for designs that require one variable at a time.
Key Research Applications
- Concurrent GHRH receptor and GHSR-1a receptor signalling studies
- Comparative pharmacology of combined versus single-compound preparations
- Pituitary somatotroph cell function research
- GH pulse kinetics characterisation in animal models
- IGF-1 axis downstream marker measurement in animal models
Technical Specifications
| Composition | CJC-1295 (No DAC) 10mg + Ipamorelin 10mg |
| Total Peptide per Vial | 20mg |
| CAS Numbers | 863288-34-0 (CJC-1295 No DAC); 170851-70-4 (Ipamorelin) |
| Mechanism | GHRH receptor agonist + GHSR-1a (ghrelin receptor) agonist |
| Purity | ≥98% (supplier specification) |
| Form | Lyophilized powder |
| Storage | −4 °F long-term |
FOR RESEARCH USE ONLY. Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting.
Not sure which compounds fit your research? Browse the Research Hub →
- Processing: Orders ship within 1–2 business days
- Domestic delivery: 3–5 business days via USPS Priority / UPS Ground
- Free shipping on orders over $100
- Temperature handling: Cold-chain packaging available on request for lyophilized peptides
- Tracking: Emailed automatically at time of dispatch
- Store lyophilized (dry) peptides at −4 °F for long-term stability
- Protect from light and moisture at all times
- Do not freeze
- Where the Storage row in the product specification above differs, follow the specification
Pairs Well With
Related research products
Reviews
There are no reviews yet.